IFN-beta Protein, Human, Recombinant

产品编号 TMPY-03145

IFN-beta Protein, Human, Recombinant is expressed in CHO mammalian cells. The predicted molecular weight is 20 kDa and the accession number is P01574.

IFN-beta Protein, Human, Recombinant

产品编号 TMPY-03145

IFN-beta Protein, Human, Recombinant is expressed in CHO mammalian cells. The predicted molecular weight is 20 kDa and the accession number is P01574.

规格	价格	库存
20 μg	¥ 1,950	现货
100 μg	¥ 4,430	5日内发货
200 μg	¥ 7,830	5日内发货
500 μg	¥ 16,550	5日内发货

大包装 & 定制

加入购物车

实验操作小课堂

选择批次

资源下载

COA 重组蛋白用户指南

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

产品信息

生物活性	Measured in antiviral assays using WISH cells infected with vesicular stomatitis virus. The ED50 for this effect is typically 2-20 pg/mL.
产品描述	IFN-beta Protein, Human, Recombinant is expressed in CHO mammalian cells. The predicted molecular weight is 20 kDa and the accession number is P01574.
种属	Human
表达系统	CHO Cells
标签	Tag Free
蛋白编号	P01574
别名	干扰素,interferon, β1, fibroblast,interferon, beta 1, fibroblast,Interferon β,Interferon beta,IFN-β,IFN-beta,IFNB,IFF,IFB
蛋白构建	A DNA sequence encoding the human IFNβ (P01574) (Met1-Asn187) was expressed. Predicted N terminal: Met 22
蛋白纯度	> 95 % as determined by SDS-PAGE
分子量	20 kDa (predicted); 20-23 kDa (reducing conditions)
内毒素	< 1.0 EU/μg of the protein as determined by the LAL method.
缓冲液	Lyophilized from a solution filtered through a 0.22 μm filter, containing 10 mM NaAC, 40 mM Arg, 0.12mg/ml Met, 146mg/ml Sucrose, 0.1% PF-68, pH 4. 5. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
复溶方法	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
存储	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	In general, Lyophilized powders are shipping with blue ice.
研究背景	Interferons (IFNs) are natural glycoproteins belonging to the cytokine superfamily and are produced by the cells of the immune system of most vertebrates in response to challenges by foreign agents such as viruses, parasites, and tumor cells. Interferon-beta (IFN beta) is an extracellular protein mediator of host defense and homeostasis. IFN beta has well-established direct antiviral, antiproliferative, and immunomodulatory properties. Recombinant IFN beta is approved for the treatment of relapsing-remitting multiple sclerosis. The recombinant IFN beta protein has the theoretical potential to either treat or causes autoimmune neuromuscular disorders by altering the complicated and delicate balances within the immune system networks. It is the most widely prescribed disease-modifying therapy for multiple sclerosis (MS). Large-scale clinical trials have established the clinical efficacy of IFN beta in reducing relapses and slowing disease progression in relapsing-remitting MS. IFN beta therapy was shown to be comparably beneficial for opticospinal MS (OSMS) and conventional MS in Japanese. IFN beta is effective in reducing relapses in secondary progressive MS and may have a modest effect in slowing disability progression. In addition to the common antiviral activity, IFN beta also induces increased production of the p53 gene product which promotes apoptosis and thus has a therapeutic effect against certain cancers. The role of IFN-beta in bone metabolism could warrant its systematic evaluation as a potential adjunct to therapeutic regimens of osteolytic diseases. Furthermore, IFN beta might play a beneficial role in the development of chronic progressive CNS inflammation.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy